CN112402288A - Anti-aging polypeptide composition and application thereof - Google Patents
Anti-aging polypeptide composition and application thereof Download PDFInfo
- Publication number
- CN112402288A CN112402288A CN202011428339.3A CN202011428339A CN112402288A CN 112402288 A CN112402288 A CN 112402288A CN 202011428339 A CN202011428339 A CN 202011428339A CN 112402288 A CN112402288 A CN 112402288A
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- polypeptide composition
- aging
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 47
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 30
- 235000013361 beverage Nutrition 0.000 claims abstract description 19
- 102000004190 Enzymes Human genes 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 13
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 12
- 229940026510 theanine Drugs 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 239000003085 diluting agent Substances 0.000 claims abstract description 3
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 3
- 239000006041 probiotic Substances 0.000 claims abstract description 3
- 230000000529 probiotic effect Effects 0.000 claims abstract description 3
- 235000018291 probiotics Nutrition 0.000 claims abstract description 3
- 235000013311 vegetables Nutrition 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
- 235000015205 orange juice Nutrition 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 5
- 230000003169 placental effect Effects 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 3
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 3
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 240000003394 Malpighia glabra Species 0.000 claims description 3
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 235000013997 pineapple juice Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 240000006432 Carica papaya Species 0.000 claims description 2
- 235000009467 Carica papaya Nutrition 0.000 claims description 2
- 244000000626 Daucus carota Species 0.000 claims description 2
- 235000002767 Daucus carota Nutrition 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 55
- 230000004888 barrier function Effects 0.000 abstract description 16
- 230000036737 immune function Effects 0.000 abstract description 14
- 230000004060 metabolic process Effects 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 10
- 230000001105 regulatory effect Effects 0.000 abstract description 9
- 239000003102 growth factor Substances 0.000 abstract description 8
- 230000003860 sleep quality Effects 0.000 abstract description 8
- 230000004936 stimulating effect Effects 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 238000005502 peroxidation Methods 0.000 abstract description 7
- 230000008929 regeneration Effects 0.000 abstract description 7
- 238000011069 regeneration method Methods 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 210000004927 skin cell Anatomy 0.000 abstract description 6
- 206010008570 Chloasma Diseases 0.000 abstract description 5
- 208000003351 Melanosis Diseases 0.000 abstract description 5
- 230000010261 cell growth Effects 0.000 abstract description 5
- 210000000130 stem cell Anatomy 0.000 abstract description 5
- 230000037303 wrinkles Effects 0.000 abstract description 5
- 238000009499 grossing Methods 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 210000003743 erythrocyte Anatomy 0.000 description 28
- 238000012360 testing method Methods 0.000 description 26
- 102000001554 Hemoglobins Human genes 0.000 description 17
- 108010054147 Hemoglobins Proteins 0.000 description 17
- 230000032683 aging Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 210000003979 eosinophil Anatomy 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 230000036039 immunity Effects 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an anti-aging polypeptide composition for improving sleep quality, regulating intestinal flora balance and relieving chloasma and application thereof, wherein the first component comprises a polypeptide composition and a diluent, and the second component comprises a vegetable and fruit enzyme probiotic solid beverage; the third component comprises a compound theanine solid beverage, the anti-aging polypeptide composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and eliminate free radicals; the cell growth factor group contained in the composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and remove free radicals, thereby stimulating the growth of skin cells, accelerating metabolism, stimulating the regeneration of stem cells per se, providing necessary nutrition for skin, smoothing fine wrinkles, restoring the skin to be in an elastic young state, regulating the water loss of the skin, repairing dry cuticle, improving the quality of a skin protection barrier, restoring the natural barrier of the skin, enabling the skin to become soft, smooth and elastic and relieving chloasma.
Description
Technical Field
The invention relates to an anti-aging polypeptide composition for improving sleep quality, regulating balance of intestinal flora and improving immunity and application thereof.
Background
Aging is a process in which after the body passes through a sexual maturity period, the self-renewal and repair ability of cells is weakened, the structure and function of tissues and organs are degraded, and finally death is caused, and is characterized in that the stress ability is reduced, the equilibrium state is broken, and the risk of suffering from diseases is increased. With the aging of the global population, various degenerative diseases of the aged and the consequent enormous medical expenses have become increasingly serious social problems. The maintenance of the health state of the elderly population is a key link for reducing the social burden and the economic burden brought by the aging of the population. Therefore, the method and the measure for intervening aging and aging-related diseases, which are simple, convenient, feasible, economical, effective and high in safety and are suitable for popularization, have great significance.
To date, the most common anti-aging modality is the use of anti-aging drugs. The drugs for delaying aging used clinically are mostly synthetic drugs, for example, vitamin E can promote cell division and inhibit the generation of oxygen free radicals, procaine preparation can prolong the cell life, amidopirenone can delay brain aging, etc.; aspirin delays the decline in body function caused by aging by combating oxidative stress.
Skin aging is a phenomenon of skin aging caused by natural factors or non-natural factors. After birth, the skin tissue of a person is increasingly developed, the function of the person is gradually activated, the person starts to degenerate when the person reaches a certain age, and the degeneration of the seed transportation is gradually carried out unconsciously. The growth period of skin tissue generally ends at about 25 years old, which is generally called as "skin bend angle", since the growth and aging of skin occur simultaneously, the elastic fibers of skin gradually become thick, and the aging of skin gradually becomes obvious when the age reaches the early stage from 40 to 50 years old, but the aging degree varies from person to person. As the skin ages, the thickness of the skin gradually becomes thinner with atrophy, subcutaneous fat is reduced, and elasticity and tension of the skin gradually lose due to changes in elastic fibers and collagen fibers, thereby further causing skin sagging and wrinkle generation.
In the field of medical beauty treatment and anti-aging at present, facial anti-aging is commonly adopted, such as photoelectric treatment of hot Maji and the like, beauty treatment of hand-needle injection and the like, and the aging index is not only the facial skin relaxation, but also the sleep and intestinal index decline.
The existing means only improve the facial problem, cannot resist aging from the inside of a human body, and cannot solve the inherent problems of sleep, intestinal health and the like.
For example, chinese patent publication No.: CN107823092A, published: 2018-03-23, entitled anti-aging polypeptide composition, and a preparation method and application thereof, wherein the polypeptide composition comprises the following components in parts by weight, based on 100 parts by weight of the polypeptide composition: 1-10 parts of palmitoyl tetrapeptide-7, 1-10 parts of palmitoyl tripeptide-5, 1-10 parts of acetyl tetrapeptide-5, 5-15 parts of palmitoyl oligopeptide, 5-20 parts of oat peptide, 5-20 parts of wild soybean peptide, 2-15 parts of tremella extract, 0.05-0.5 part of dry cell secretion factor and the balance of water. The polypeptide composition can be used for preparing cosmetics, has good application prospects in the fields of anti-wrinkle repair and anti-aging skin care products, and can enable skin to be picked up, tight, fine and smooth, distinguished dark, rough and restore the skin to a young health state. The disclosure of this patent is solely to eliminate inflammation by promoting collagen and other extracellular matrix proteins; after the use is stopped, the skin still slowly ages, the skin cannot resist aging from the inside of the human body, and the inherent problems of sleep, intestinal health and the like cannot be solved.
Disclosure of Invention
The invention aims to provide an anti-aging polypeptide composition for improving sleep quality, regulating intestinal flora balance and improving immunity in order to overcome the defects that the existing anti-aging composition cannot resist aging from the interior of an organism and cannot solve the inherent problems of sleep, intestinal health and the like.
The invention also provides application of the anti-aging polypeptide composition.
In order to achieve the purpose, the invention adopts the following technical scheme:
an anti-aging polypeptide composition comprises 1-10 parts of a first component, 1-30 parts of a second component and 1-30 parts of a third component; wherein the first component comprises a polypeptide composition and a diluent; the second component comprises vegetable and fruit enzyme probiotic solid beverage; the third component comprises a compound theanine solid beverage.
In the technical scheme, the polypeptide composition is used for increasing microcirculation, improving metabolism level, enhancing physiological functions, improving immunity, regulating and balancing endocrine, prolonging puberty, repairing injured skin tissues, dissolving aged cutin, recovering skin youth state and inhibiting inflammation and resisting allergy;
let user's sleep quality promote, promptly: the improvement of shortening the time of falling asleep, increasing the time of deep sleep, reducing the nighttime dreaminess and the like, thereby eliminating the fatigue of the skin, keeping the regulation activity of skin cells normal and delaying the aging of the skin; the cell growth factor group contained in the polypeptide composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and remove free radicals, thereby stimulating the growth of skin cells, accelerating metabolism, stimulating the regeneration of stem cells per se, providing necessary nutrition for skin, smoothing fine wrinkles, restoring the skin to be in an elastic young state, regulating the water loss of the skin, repairing dry cuticle, improving the quality of a skin protection barrier, restoring the natural barrier of the skin, enabling the skin to become soft, smooth and elastic and relieving chloasma.
On the basis of delaying skin aging, the solid beverage containing the second component and the third component is used for regulating the balance of intestinal flora, and is beneficial to improving the normal physiological metabolism of a human body, improving the barrier function of intestinal tracts and reducing the generation of metabolic endotoxin, so that the skin immunity function is improved, the natural barrier of the skin is recovered, and the skin becomes soft, smooth and elastic.
Meanwhile, the third component can further improve the sleep quality.
In a preferred embodiment of the present invention, the first component is a composition of placental polypeptide and physiological saline.
As a preferred embodiment of the present invention, the content of the placental polypeptide in the first component is: 0.1-2 mL.
As a preferable embodiment of the present invention, the content of the physiological saline in the first component is: 5-10 mL.
As a preferable scheme of the invention, the second component comprises the following raw materials in parts by weight: 1-5 parts of resistant dextrin, 2-15 parts of pectin, 2-10 parts of acerola powder, 1-10 parts of orange juice powder, 3-5 parts of lactobacillus acidophilus, 3-5 parts of bifidobacterium animalis, 15-20 parts of comprehensive fruit and vegetable enzyme powder, 10-15 parts of orange powder, 1-5 parts of stevioside and 0.1-0.3 part of essence for food.
As a preferable scheme of the invention, the third component comprises the following raw materials in parts by weight: 1-5 parts of resistant dextrin, 2-10 parts of pectin, 3-10 parts of orange juice powder, 2-8 parts of pineapple juice powder, 1-5 parts of crystalline fructose, 10-15 parts of lemon juice powder, 30-50 parts of tea theanine, 15-25 parts of gamma-aminobutyric acid, 1-5 parts of sodium citrate, 1-5 parts of stevioside and 0.1-0.3 part of essence for food.
As a preferred scheme of the invention, the comprehensive fruit and vegetable enzyme powder comprises pineapple enzyme, papaya enzyme and carrot enzyme in a mass ratio of 1:2-5: 5-10.
An application of an anti-aging polypeptide composition in the cosmetic industry.
Compared with the prior art, the invention has the following beneficial effects:
1) the anti-aging polypeptide composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and eliminate free radicals;
2) the cell growth factor group contained in the anti-aging polypeptide composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and remove free radicals, thereby stimulating the growth of skin cells, accelerating metabolism, stimulating the regeneration of stem cells per se, providing necessary nutrition for skin, smoothing fine wrinkles, restoring the skin to be in an elastic young state, regulating the water loss of the skin, repairing dry cuticle, improving the quality of a skin protection barrier, restoring the natural barrier of the skin, enabling the skin to become soft, smooth and elastic, and relieving chloasma;
3) the anti-aging polypeptide composition provided by the invention can regulate the balance of intestinal flora, is beneficial to improving the normal physiological metabolism of a human body, improving the barrier function of intestinal tracts and reducing the generation of metabolic endotoxin, thereby improving the immune function of skin and recovering the natural barrier of skin.
Detailed Description
The present invention is further described below with reference to specific embodiments, and it should be noted that, without conflict, any combination between the embodiments or technical features described below may form a new embodiment.
The placenta polypeptide is purchased from Huadongningbo medicine Co., Ltd, and comprises the following main components of amino acid, active peptide, protein, lipid fatty acid, mucopolysaccharide, vitamin, mineral, nucleic acid, enzyme and cell growth factor group: epidermal growth factor, hepatocyte growth factor, nerve cell growth factor, epithelial tissue growth factor, fibroblast growth factor, insulin-like growth factor, immunity-enhancing growth factor, etc.
The first component of the invention is to mix the placenta polypeptide composition with normal saline to prepare injection, and the injection is used; wherein the content of the placenta polypeptide composition in the injection is 0.1mL, 0.5mL, 1mL or 2mL, and the volume is determined to be 5-10mL by using normal saline.
The second component of the invention is solid beverage prepared by mixing 1-5 parts of resistant dextrin, 2-15 parts of pectin, 2-10 parts of acerola cherry powder, 1-10 parts of orange juice powder, 3-5 parts of lactobacillus acidophilus, 3-5 parts of bifidobacterium animalis, 15-20 parts of comprehensive fruit and vegetable ferment powder, 10-15 parts of orange powder, 1-5 parts of stevioside and 0.1-0.3 part of essence for food, and the solid beverage is taken with warm water after half an hour of breakfast.
The third component of the invention is that 1 to 5 parts of resistant dextrin, 2 to 10 parts of pectin, 3 to 10 parts of orange juice powder, 2 to 8 parts of pineapple juice powder, 1 to 5 parts of crystalline fructose, 10 to 15 parts of lemon juice powder, 30 to 50 parts of tea theanine, 15 to 25 parts of gamma-aminobutyric acid, 1 to 5 parts of sodium citrate, 1 to 5 parts of stevioside and 0.1 to 0.3 part of food essence are mixed to prepare solid beverage, and the solid beverage is taken with warm water half an hour before falling asleep.
Examples
Immunomodulation
Injecting acupuncture points:
acupoints, Zusanli, Sanyinjiao, Taichong, Zhang, and sleeping.
Injection dose (based on the content of the placental polypeptide composition):
the first 0.5mL, then 1mL, without special cases.
Zusanli, Sanyinjiao, Taichong and interline 1mL for the first time, and then 2mL for each time without special conditions.
Sleep 0.1 mL.
Example 2:
testing the immunoregulation efficacy:
this example is the usage detection procedure and results of example 1.
The number of test persons was 3.
The test method comprises the following steps: the placenta polypeptide injection is adopted, 1 bag of daily beverage is taken half an hour after breakfast, 1 bag of night beverage is taken half an hour before sleeping, 3 days are stopped for 3 days after placenta polypeptide injection, 3 days are continued, and the daily solid beverage and the night solid beverage are taken orally for one month.
The test adopts whole blood detection, detection indexes comprise a white blood cell index, a red blood cell index, a lymphocyte index and the like, whether the indexes are within a reference value range or not is observed, whether the indexes have an ascending trend or not is observed so as to judge whether the human body immunity function is normal or not, and the detection result is shown in the following table.
The test period is 30 days, the detection index before the test is shown in table 1, and the detection index after the test is shown in table 2 after the test for 30 days.
The tester 2 is female, the age is 51 years old, the first 1mL between Zusanli, Sanyinjiao, Taichong and Xinghua, and the second 2mL without special conditions; the placenta polypeptide injection is stopped for 3 days, the injection is continuously taken for 3 days, the beverage is taken for 1 bag every half hour after breakfast, the beverage is taken for 1 bag every half hour before sleeping, the test period is 30 days, the detection index before test is shown in table 3, and the detection index after test for 30 days is shown in table 4.
The testee No. 3, female, age 51 years old, Zusanli, Sanyinjiao, Taichong, interrow first 1mL, no special condition after 2mL each time; 0.1mL of sleep; the placenta polypeptide injection is stopped for 3 days, the injection is continuously taken for 3 days, the beverage is taken for 1 bag every half hour after breakfast, the beverage is taken for 1 bag every half hour before sleeping, the test period is 30 days, the detection index before test is shown in table 5, and the detection index after test for 30 days is shown in table 6.
TABLE 1 tester No. 1 pre-test detection index
TABLE 2 test indexes after tester No. 1 test
| Numbering | Inspection item | Test results | Unit of | Reference value |
| 1 | White Blood Cell (WBC) | 6.38 | 10^9/L | 3.5-9.5 |
| 2 | Neutrophil count [ NEU #] | 3.47 | 10^9/L | 1.8-6.3 |
| 3 | Percentage of neutrophils [ NEU% ]] | 54.3 | ％ | 40-75 |
| 4 | Lymphocyte count [ LYM #] | 2.00 | 10^9/L | 1.1-3.2 |
| 5 | Lymphocyte percentage [ LYM%] | 31.4 | ％ | 20-50 |
| 6 | Monocyte count [ MON # ]] | 0.19 | 10^9/L | 0.1-0.6 |
| 7 | Percentage of monocytes [ MON% ]] | 3.0 | ％ | 3-10 |
| 8 | Eosinophil count [ EOS #] | 0.70 | 10^9/L | 0.02-0.52 |
| 9 | Percentage of eosinophils [ EOS%] | 11.0 | ％ | 0.4-8.0 |
| 10 | Basophilic granulocyte count [ BAS #] | 0.02 | 10^9/L | 0-0.06 |
| 11 | Basophilic percentage [ BAS%] | 0.3 | ％ | 0.0-1.0 |
| 12 | Red blood cells [ RBC] | 3.35 | 10^12/L | 4.3-5.8 |
| 13 | Hemoglobin [ HGB] | 116 | g/L | 130-175 |
| 14 | Hematocrit [ HCT ]] | 36.00 | ％ | 40-50 |
| 15 | Mean volume of erythrocytes [ MCV] | 107.4 | fL | 82-100 |
| 16 | Mean amount of hemoglobin [ MCH] | 34.5 | pg | 27.8-33.8 |
| 17 | Mean hemoglobin concentration [ MCHC ]] | 322 | g/L | 316-354 |
| 18 | Erythrocyte distribution Width CV [ RDW-CV ]] | 17.2 | ％ | 11-14.5 |
| 19 | Erythrocyte distribution Width SD [ RDW-SD ]] | 77.7 | fL | 37-51 |
| 20 | Platelets [ PLT ]] | 185 | 10^9/L | 125-350 |
| 21 | Platelet volume [ PCT ]] | 0.17 | ％ | 0.11-0.28 |
| 22 | Mean platelet volume [ MPV ]] | 9.3 | fL | 6.5-13 |
| 23 | Width of platelet distribution [ PDW] | 16.4 | fL | 9-17 |
As can be seen from the detection data in tables 1 and 2, the increase in the leukocyte index of the tester 1 for a month is 2.84, and the increase in the platelet index for a month is 66, which indicates that the immunoglobulin of the tester 1 is increased, and the cellular immune function of the tester 1 is improved, so that the defense function of the body is improved, and the immunity is improved; the red blood cell single month rising 1.6 and the hemoglobin single month rising 39 promote the regeneration of the bone marrow hematopoietic cells of the No. 1 testee, replenish qi and blood, relieve nervous anxiety, improve the sleep quality and delay senility.
TABLE 3 Pre-test detection index for tester 2
| Numbering | Inspection item | Test results | Unit of | Reference value |
| 1 | White Blood Cell (WBC) | 3.99 | 10^9/L | 3.5-9.5 |
| 2 | Neutrophil count [ NEU #] | 2.52 | 10^9/L | 2-7 |
| 3 | Percentage of neutrophils [ NEU% ]] | 63.0 | ％ | 50.0-70.0 |
| 4 | Lymphocyte count [ LYM #] | 1.22 | 10^9/L | 0.8-4 |
| 5 | Lymphocyte percentage [ LYM%] | 30.5 | ％ | 20-40 |
| 6 | Monocyte count [ MON # ]] | 0.19 | 10^9/L | 0.12-1.2 |
| 7 | Percentage of monocytes [ MON% ]] | 4.8 | ％ | 3-12 |
| 8 | Eosinophil count [ EOS #] | 0.05 | 10^9/L | 0.02-0.5 |
| 9 | Percentage of eosinophils [ EOS%] | 1.4 | ％ | 0.5-5.0 |
| 10 | Basophilic granulocyte count [ BAS #] | 0.01 | 10^9/L | 0-1 |
| 11 | Basophilic percentage [ BAS%] | 0.3 | ％ | 0.0-1.0 |
| 12 | Red blood cells [ RBC] | 3.6 | 10^12/L | 3.5-5.5 |
| 13 | Hemoglobin [ HGB] | 119 | g/L | 110-160 |
| 14 | Hematocrit [ HCT ]] | 37.20 | ％ | 37-54 |
| 15 | Mean volume of erythrocytes [ MCV] | 103.1 | fL | 80-100 |
| 16 | Mean amount of hemoglobin [ MCH] | 33.0 | pg | 27-34 |
| 17 | Mean hemoglobin concentration [ MCHC ]] | 320 | g/L | 320-360 |
| 18 | Erythrocyte distribution Width CV [ RDW-CV ]] | 13 | ％ | 11-16 |
| 19 | Erythrocyte distribution Width SD [ RDW-SD ]] | 55 | fL | 35-56 |
| 20 | Platelets [ PLT ]] | 209 | 10^9/L | 100-300 |
| 21 | Platelet volume [ PCT ]] | 0.187 | ％ | 0.108-0.282 |
| 22 | Mean platelet volume [ MPV ]] | 8.9 | fL | 6.5-12 |
| 23 | Width of platelet distribution [ PDW] | 16.0 | fL | 9-17 |
TABLE 4 test indexes after tester 2
| Numbering | Inspection item | Test results | Unit of | Reference value |
| 1 | White Blood Cell (WBC) | 4.44 | 10^9/L | 3.5-9.5 |
| 2 | Neutrophil count [ NEU #] | 2.92 | 10^9/L | 2-7 |
| 3 | Percentage of neutrophils [ NEU% ]] | 65.7 | ％ | 50.0-70.0 |
| 4 | Lymphocyte count [ LYM #] | 1.31 | 10^9/L | 0.8-4 |
| 5 | Lymphocyte percentage [ LYM%] | 29.4 | ％ | 20-40 |
| 6 | Monocyte count [ MON # ]] | 0.16 | 10^9/L | 0.12-1.2 |
| 7 | Percentage of monocytes [ MON% ]] | 3.7 | ％ | 3-12 |
| 8 | Eosinophil count [ EOS #] | 0.04 | 10^9/L | 0.02-0.5 |
| 9 | Percentage of eosinophils [ EOS%] | 0.9 | ％ | 0.5-5.0 |
| 10 | Basophilic granulocyte count [ BAS #] | 0.01 | 10^9/L | 0-1 |
| 11 | Basophilic percentage [ BAS%] | 0.3 | ％ | 0.0-1.0 |
| 12 | Red blood cells [ RBC] | 3.98 | 10^12/L | 3.5-5.5 |
| 13 | Hemoglobin [ HGB] | 127 | g/L | 110-160 |
| 14 | Hematocrit [ HCT ]] | 40.6 | ％ | 37-54 |
| 15 | Mean volume of erythrocytes [ MCV] | 102.2 | fL | 80-100 |
| 16 | Mean amount of hemoglobin [ MCH] | 31.9 | pg | 27-34 |
| 17 | Mean hemoglobin concentration [ MCHC ]] | 312 | g/L | 320-360 |
| 18 | Erythrocyte distribution Width CV [ RDW-CV ]] | 12 | ％ | 11-16 |
| 19 | Erythrocyte distribution Width SD [ RDW-SD ]] | 53 | fL | 35-56 |
| 20 | Platelets [ PLT ]] | 211 | 10^9/L | 100-300 |
| 21 | Platelet volume [ PCT ]] | 0.206 | ％ | 0.108-0.282 |
| 22 | Mean platelet volume [ MPV ]] | 9.8 | fL | 6.5-12 |
| 23 | Width of platelet distribution [ PDW] | 9.8 | fL | 9-17 |
As can be seen from the detection data in tables 3 and 4, the leukocyte index of the tester 2 increases by 0.45 a month, the cellular immune function of the tester 2 is improved, the defense function of the organism is improved, and the immunity is enhanced; the red blood cell single month rising is 0.38, the hemoglobin single month rising is 8, the regeneration of the bone marrow hematopoietic cells of the tester No. 2 is promoted, qi and blood are supplemented, the nervous anxiety is relieved, the sleep quality is improved, and the aging is delayed, so that the growth of skin cells can be stimulated, the metabolism is accelerated, the regeneration of stem cells per se is stimulated, the normal physiological metabolism of a human body is improved, the intestinal barrier function is improved, the generation of metabolic endotoxin is reduced, the skin immunologic function is improved, and the natural barrier of the skin is recovered.
TABLE 5 Pre-test detection index for tester No. 3
| Numbering | Inspection item | Test results | Unit of | Reference value |
| 1 | White Blood Cell (WBC) | 3.05 | 10^9/L | 3.5-9.5 |
| 2 | Neutrophil count [ NEU #] | 1.80 | 10^9/L | 2-7 |
| 3 | Percentage of neutrophils [ NEU% ]] | 58.7 | ％ | 50.0-70.0 |
| 4 | Lymphocyte meterNumber [ LYM # ]] | 1.07 | 10^9/L | 0.8-4 |
| 5 | Lymphocyte percentage [ LYM%] | 35.0 | ％ | 20-40 |
| 6 | Monocyte count [ MON # ]] | 0.13 | 10^9/L | 0.12-1.2 |
| 7 | Percentage of monocytes [ MON% ]] | 4.4 | ％ | 3-12 |
| 8 | Eosinophil count [ EOS #] | 0.04 | 10^9/L | 0.02-0.5 |
| 9 | Percentage of eosinophils [ EOS%] | 1.4 | ％ | 0.5-5.0 |
| 10 | Basophilic granulocyte count [ BAS #] | 0.01 | 10^9/L | 0-1 |
| 11 | Basophilic percentage [ BAS%] | 0.5 | ％ | 0.0-1.0 |
| 12 | Red blood cells [ RBC] | 4.20 | 10^12/L | 3.5-5.5 |
| 13 | Hemoglobin [ HGB] | 135 | g/L | 110-160 |
| 14 | Hematocrit [ HCT ]] | 42.40 | ％ | 37-54 |
| 15 | Mean volume of erythrocytes [ MCV] | 101.0 | fL | 80-100 |
| 16 | Mean amount of hemoglobin [ MCH] | 32.2 | pg | 27-34 |
| 17 | Mean hemoglobin concentration [ MCHC ]] | 319 | g/L | 320-360 |
| 18 | Erythrocyte distribution Width CV [ RDW-CV ]] | 12 | ％ | 11-16 |
| 19 | Erythrocyte distribution Width SD [ RDW-SD ]] | 52 | fL | 35-56 |
| 20 | Platelets [ PLT ]] | 181 | 10^9/L | 100-300 |
| 21 | Platelet volume [ PCT ]] | 0.190 | ％ | 0.108-0.282 |
| 22 | Mean platelet volume [ MPV ]] | 10.5 | fL | 6.5-12 |
| 23 | Width of platelet distribution [ PDW] | 16.5 | fL | 9-17 |
TABLE 6 test indexes after test No. 3 of testers
| Numbering | Inspection item | Test results | Unit of | Reference value |
| 1 | White Blood Cell (WBC) | 3.99 | 10^9/L | 3.5-9.5 |
| 2 | Neutrophil count [ NEU #] | 2.52 | 10^9/L | 2-7 |
| 3 | Percentage of neutrophils [ NEU% ]] | 63.0 | ％ | 50.0-70.0 |
| 4 | Lymphocyte count [ LYM #] | 1.22 | 10^9/L | 0.8-4 |
| 5 | Lymphocyte percentage [ LYM%] | 30.5 | ％ | 20-40 |
| 6 | Monocyte count [ MON # ]] | 0.19 | 10^9/L | 0.12-1.2 |
| 7 | Percentage of monocytes [ MON% ]] | 4.8 | ％ | 3-12 |
| 8 | Eosinophil count [ EOS #] | 0.05 | 10^9/L | 0.02-0.5 |
| 9 | Percentage of eosinophils [ EOS%] | 1.4 | ％ | 0.5-5.0 |
| 10 | Basophilic granulocyte count [ BAS #] | 0.01 | 10^9/L | 0-1 |
| 11 | Basophilic percentage [ BAS%] | 0.3 | ％ | 0.0-1.0 |
| 12 | Red blood cells [ RBC] | 3.60 | 10^12/L | 3.5-5.5 |
| 13 | Hemoglobin [ HGB] | 119 | g/L | 110-160 |
| 14 | Hematocrit [ HCT ]] | 37.20 | ％ | 37-54 |
| 15 | Mean volume of erythrocytes [ MCV] | 103.1 | fL | 80-100 |
| 16 | Mean amount of hemoglobin [ MCH] | 33.0 | pg | 27-34 |
| 17 | Mean hemoglobin concentration [ MCHC ]] | 320 | g/L | 320-360 |
| 18 | Erythrocyte distribution Width CV [ RDW-CV ]] | 13 | ％ | 11-16 |
| 19 | Erythrocyte distribution Width SD [ RDW-SD ]] | 55 | fL | 35-56 |
| 20 | Platelets [ PLT ]] | 209 | 10^9/L | 100-300 |
| 21 | Platelet volume [ PCT ]] | 0.187 | ％ | 0.108-0.282 |
| 22 | Mean platelet volume [ MPV ]] | 8.9 | fL | 6.5-12 |
| 23 | Width of platelet distribution [ PDW] | 16.0 | fL | 9-17 |
As can be seen from the detection data in tables 5 and 6, the increase in the leukocyte index of the tester 3 by 0.94 per month and the increase in the platelet index by 28 per month indicate that the cellular immune function of the tester 3 is improved, so that the defense function of the body is improved, the immunity is improved, the nervous anxiety is relieved, the sleep quality is improved, the metabolism is accelerated, the intestinal barrier function is improved, the production of metabolic endotoxin is reduced, the skin immune function is improved, and the natural barrier of the skin is restored.
The anti-aging polypeptide composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and eliminate free radicals; the cell growth factor group contained in the anti-aging polypeptide composition can enhance the immunologic function of cells, inhibit the peroxidation of organisms and remove free radicals, thereby stimulating the growth of skin cells, accelerating metabolism, stimulating the regeneration of stem cells per se, providing necessary nutrition for skin, smoothing fine wrinkles, restoring the skin to be in an elastic young state, regulating the water loss of the skin, repairing dry cuticle, improving the quality of a skin protection barrier, restoring the natural barrier of the skin, enabling the skin to become soft, smooth and elastic, and relieving chloasma; the anti-aging polypeptide composition provided by the invention can regulate the balance of intestinal flora, is beneficial to improving the normal physiological metabolism of a human body, improving the barrier function of intestinal tracts and reducing the generation of metabolic endotoxin, thereby improving the immune function of skin and recovering the natural barrier of skin.
The foregoing is a more detailed description of the present invention in connection with specific preferred embodiments thereof, and is not intended to limit the invention to the particular forms disclosed. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (8)
1. An anti-aging polypeptide composition is characterized by comprising 1-10 parts of a first component, 1-30 parts of a second component and 1-30 parts of a third component; wherein the first component comprises a polypeptide composition and a diluent; the second component comprises vegetable and fruit enzyme probiotic solid beverage; the third component comprises a compound theanine solid beverage.
2. The anti-aging polypeptide composition of claim 1, wherein the first component is an injection of placental polypeptide and physiological saline.
3. The anti-aging polypeptide composition of claim 2, wherein the placental polypeptide content of the first component is: 0.1-2 mL.
4. The anti-aging polypeptide composition of claim 2, wherein the amount of normal saline in the first component is: 5-10 mL.
5. The anti-aging polypeptide composition according to claim 1, wherein the second component comprises the following raw materials in parts by weight: 1-5 parts of resistant dextrin, 2-15 parts of pectin, 2-10 parts of acerola powder, 1-10 parts of orange juice powder, 3-5 parts of lactobacillus acidophilus, 3-5 parts of bifidobacterium animalis, 15-20 parts of comprehensive fruit and vegetable enzyme powder, 10-15 parts of orange powder, 1-5 parts of stevioside and 0.1-0.3 part of essence for food.
6. The anti-aging polypeptide composition according to claim 1, wherein the third component comprises the following raw materials in parts by weight: 1-5 parts of resistant dextrin, 2-10 parts of pectin, 3-10 parts of orange juice powder, 2-8 parts of pineapple juice powder, 1-5 parts of crystalline fructose, 10-15 parts of lemon juice powder, 30-50 parts of tea theanine, 15-25 parts of gamma-aminobutyric acid, 1-5 parts of sodium citrate, 1-5 parts of stevioside and 0.1-0.3 part of essence for food.
7. The anti-aging polypeptide composition as claimed in claim 5, wherein the comprehensive fruit and vegetable enzyme powder comprises pineapple enzyme, papaya enzyme and carrot enzyme in a mass ratio of 1:2-5: 5-10.
8. Use of an anti-aging polypeptide composition according to any one of claims 1 to 7 in the cosmetic industry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011428339.3A CN112402288A (en) | 2020-12-09 | 2020-12-09 | Anti-aging polypeptide composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011428339.3A CN112402288A (en) | 2020-12-09 | 2020-12-09 | Anti-aging polypeptide composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112402288A true CN112402288A (en) | 2021-02-26 |
Family
ID=74774957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011428339.3A Pending CN112402288A (en) | 2020-12-09 | 2020-12-09 | Anti-aging polypeptide composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112402288A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284057A (en) * | 2011-07-26 | 2011-12-21 | 贵州泰邦生物制品有限公司 | Method for preparing placenta polypeptide injection |
| CN106173772A (en) * | 2016-07-06 | 2016-12-07 | 慧谷生命科技湖北有限公司 | A kind of vegetables and fruits ferment solid beverage and preparation method thereof |
| CN107691955A (en) * | 2017-09-14 | 2018-02-16 | 广州赛莱拉干细胞科技股份有限公司 | Probiotics solid beverage and preparation method thereof |
| CN109315663A (en) * | 2018-08-27 | 2019-02-12 | 杭州维洛斯生物科技有限责任公司 | A kind of vanilla flavored albumen composite fermentation fruits and vegetables solid beverage and preparation method thereof |
| CN109966318A (en) * | 2017-12-25 | 2019-07-05 | 李芳凯 | A kind of placental peptide injection preparation method |
| CN111557449A (en) * | 2020-05-19 | 2020-08-21 | 北京美信高科科技有限责任公司 | Composition with function of improving immunity and preparation method thereof |
-
2020
- 2020-12-09 CN CN202011428339.3A patent/CN112402288A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284057A (en) * | 2011-07-26 | 2011-12-21 | 贵州泰邦生物制品有限公司 | Method for preparing placenta polypeptide injection |
| CN106173772A (en) * | 2016-07-06 | 2016-12-07 | 慧谷生命科技湖北有限公司 | A kind of vegetables and fruits ferment solid beverage and preparation method thereof |
| CN107691955A (en) * | 2017-09-14 | 2018-02-16 | 广州赛莱拉干细胞科技股份有限公司 | Probiotics solid beverage and preparation method thereof |
| CN109966318A (en) * | 2017-12-25 | 2019-07-05 | 李芳凯 | A kind of placental peptide injection preparation method |
| CN109315663A (en) * | 2018-08-27 | 2019-02-12 | 杭州维洛斯生物科技有限责任公司 | A kind of vanilla flavored albumen composite fermentation fruits and vegetables solid beverage and preparation method thereof |
| CN111557449A (en) * | 2020-05-19 | 2020-08-21 | 北京美信高科科技有限责任公司 | Composition with function of improving immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amagase et al. | Immunomodulatory effects of a standardized Lycium barbarum fruit juice in Chinese older healthy human subjects | |
| Amagase et al. | Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults | |
| CN108498780B (en) | Composition for invigorating kidney and strengthening yang | |
| JP5312727B2 (en) | A plant-based formulation for improving the moisture retention, texture and appearance of the skin | |
| US20220072096A1 (en) | Whey protein micelles against muscle atrophy and sarcopenia | |
| Chen et al. | Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells | |
| CN109310714A (en) | For treating and preventing gastrointestinal inflammatory Pu Shi bacillus faecalis bacterial strain CNCM I-4573 | |
| CN110037268A (en) | A kind of beautifying face and moistering lotion jelly and preparation method thereof improving sleep | |
| CN105902477B (en) | The comprehensive biological agent and preparation method thereof for improving eye vigor | |
| Raymond et al. | Pain thresholds in obese binge-eating disorder subjects | |
| De la Fuente et al. | Changes in macrophage and lymphocyte functions in guinea-pigs after different amounts of vitamin E ingestion | |
| Takaoka et al. | Effect of amino-acid intake on physical conditions and skin state: a randomized, double-blind, placebo-controlled, crossover trial | |
| CN112402288A (en) | Anti-aging polypeptide composition and application thereof | |
| KR102215667B1 (en) | Composition for skin regeneration and anti-aging comprising peripheral blood-derived mononuclear cells and platelet-rich plasma, and skin regeneration method using the same | |
| CN103385890B (en) | A kind of preparation method of anti-ageing biological cell preparation | |
| KR101704539B1 (en) | Composition for anti-allergy and skin hydration comprising sedum kamtschaticum extracts | |
| ABDEL‐MALEK et al. | Proliferation and propagation of human melanocytes in vitro are affected by donor age and anatomical site | |
| Lin et al. | An examination of Lactobacillus paracasei GKS6 and Bifidobacterium lactis GKK2 isolated from infant feces in an aged mouse model | |
| CN109198347A (en) | A kind of soybean peptide solid beverage and its application | |
| CN116076710A (en) | Rose herbal ferment with anti-aging and whitening functions and preparation method and application thereof | |
| Yoshitake et al. | Beneficial Effect of Heat-Killed Lactiplantibacillus plantarum L-137 on Skin Functions in Healthy Participants: A Randomized, Placebo-Controlled, Double-Blind Study | |
| Yonei et al. | A placebo-controlled, randomized, single-blind, parallel-group comparative study to evaluate the anti-glycation effect of a functional soymilk beverage supplemented with rice bran/rice bran oil | |
| CN110214955B (en) | Composition with function of nourishing ovaries and preparation method thereof | |
| CN111450035A (en) | Pure natural pleura capable of whitening and enlarging breast and preventing and treating breast diseases and preparation method thereof | |
| Victor et al. | Comparative study of peritoneal macrophage functions in mice receiving lethal and non-lethal doses of LPS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210226 |